MEDIA ADVISORY – Survivors of residential schools to hold a media availability at the Survivors’ Flag re-raising event on Parliament Hill
OTTAWA, ON, Sept. 27, 2024 /CNW/ – Survivors of residential schools will hold a media availability for the “Re-raising of the Survivors’ Flag Ceremony” on Parliament Hill. Media participation: No virtual option is available. Members of the media are invited to attend and as
ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND, INC. REPORTS THIRD QUARTER EARNINGS
NEW YORK, Sept. 27, 2024 /PRNewswire/ — AllianceBernstein National Municipal Income Fund, Inc. (NYSE: AFB), a registered closed‑end investment company, today announced earnings for the Fund’s third fiscal quarter ended July 31, 2024. Total net assets of the Fund* on July 31, 2024 were
SIGMA LITHIUM HOSTED 2024 INVESTOR DAY, DETAILING A LOW CAPEX CONSTRUCTION PLAN TO TRIPLE CAPACITY TO 125,000t LCE BY END-2026; RECOGNIZED AS CLIMATE PIONEER BY NASDAQ
On 24 September, Sigma Lithium hosted its 2024 Investor Day, marking the first year of production and its record-setting ramp-up of its industrial Greentech Plant.The Company outlined its capital-efficient construction plans to reach approximately 125,000 t/y LCE of industrial capacity by 2026, ceme
FDA Roundup: September 27, 2024
SILVER SPRING, Md., Sept. 27, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA updated the Mycotoxins in Domestic and Imported Human Foods Compliance Program to include monitoring of addi
USCF ANNOUNCES CHANGES TO PRODUCT LINE
WALNUT CREEK, Calif., Sept. 27, 2024 /PRNewswire/ — USCF, a leading-edge provider of exchange traded product innovation, announced today that it plans to close and liquidate one of its products as a result of a decision and vote by the Board of Trustees of USCF ETF Trust that approved the liqu
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting to
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson & John
DonutNV Launches “Sleigh The Holiday” Giveaway for Corporate Events
Win a FREE DonutNV Truck Visit for Your Corporate Holiday Event! ORLANDO, Fla., Sept. 27, 2024 /PRNewswire/ — DonutNV, the beloved mobile food trucks serving hot, fresh mini donuts and refreshing lemonade and iced coffee, is excited to announce the launch of its “Sleigh The Holiday”
AT&T Declares Dividends on Common and Preferred Shares
DALLAS, Sept. 27, 2024 /PRNewswire/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares, payable November 1, 2024. Key Takeaways: The board of directors declared a quarterly dividend of $0.2775 per share on the company’s
Twelve U.S. health systems receive top honor for excellence in supply chain practices from ECRI
ECRI Announces the 2024 Healthcare Supply Chain Excellence Award Winners PLYMOUTH MEETING, Pa., Sept. 27, 2024 /PRNewswire/ — ECRI, a global patient safety nonprofit organization, announced the winners of its 2024 Healthcare Supply Chain Excellence Award. ECRI’s annual award recognizes U
